Literature DB >> 18644346

Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma.

Ying Guo1, Sanja Pajovic, Brenda L Gallie.   

Abstract

It is still not clear whether the p53 pathway is altered in retinoblastoma development. We assessed the expression of the p53 pathway genes p14(ARF), mouse double minute 2 (MDM2), and mouse double minute 4 (MDM4) in human retinoblastoma compared to normal retina. Primary human retinoblastomas, retinoblastoma cell lines and normal retinas were assessed for p14(ARF) and MDM4 mRNA by quantitative RT-PCR. p14(ARF), MDM2, and MDM4 protein were measured by immunoblot and immunohistochemistry. Compared to retina, p14(ARF) mRNA expression was notably increased in retinoblastoma but p14(ARF) protein was undetectable. MDM2 and MDM4 proteins were expressed in 22/22 retinoblastomas. MDM2 was expressed in 3/10 retinas tested, and MDM4 in 10/10 retinas. The expression level of MDM2 protein in retinoblastomas and retina was comparable, while MDM4 protein was overexpressed in one retinoblastoma cell line Y79 and two primary retinoblastomas. We observe that overexpression of MDM2 and MDM4 is not a necessary step in retinoblastoma development. However, loss of detectable p14(ARF) protein and resultant lack of functional inactivation of these p53 inhibitors may contribute to retinoblastoma development by constitutive inhibition of p53.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644346      PMCID: PMC2597893          DOI: 10.1016/j.bbrc.2008.07.055

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  36 in total

1.  Isolation and identification of the human homolog of a new p53-binding protein, Mdmx.

Authors:  A Shvarts; M Bazuine; P Dekker; Y F Ramos; W T Steegenga; G Merckx; R C van Ham; W van der Houven van Oordt; A J van der Eb; A G Jochemsen
Journal:  Genomics       Date:  1997-07-01       Impact factor: 5.736

2.  p53 regulates apoptosis in human retinoblastoma.

Authors:  T M Nork; G L Poulsen; L L Millecchia; R G Jantz; R W Nickells
Journal:  Arch Ophthalmol       Date:  1997-02

3.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.

Authors:  R Honda; H Tanaka; H Yasuda
Journal:  FEBS Lett       Date:  1997-12-22       Impact factor: 4.124

4.  MDMX: a novel p53-binding protein with some functional properties of MDM2.

Authors:  A Shvarts; W T Steegenga; N Riteco; T van Laar; P Dekker; M Bazuine; R C van Ham; W van der Houven van Oordt; G Hateboer; A J van der Eb; A G Jochemsen
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

5.  Characterization of a new continuous cell line derived from a human retinoblastoma.

Authors:  R C McFall; T W Sery; M Makadon
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

6.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

7.  Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.

Authors:  T Kamijo; F Zindy; M F Roussel; D E Quelle; J R Downing; R A Ashmun; G Grosveld; C J Sherr
Journal:  Cell       Date:  1997-11-28       Impact factor: 41.582

8.  ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

Authors:  Y Zhang; Y Xiong; W G Yarbrough
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

9.  The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

Authors:  J Pomerantz; N Schreiber-Agus; N J Liégeois; A Silverman; L Alland; L Chin; J Potes; K Chen; I Orlow; H W Lee; C Cordon-Cardo; R A DePinho
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

10.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

Authors:  T Kamijo; J D Weber; G Zambetti; F Zindy; M F Roussel; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

View more
  12 in total

Review 1.  Regulation of the human catalytic subunit of telomerase (hTERT).

Authors:  Michael Daniel; Gregory W Peek; Trygve O Tollefsbol
Journal:  Gene       Date:  2012-02-13       Impact factor: 3.688

Review 2.  Therapeutic targeting of oncogenic transcription factors by natural products in eye cancer.

Authors:  Michelle G Zhang; John Y Lee; Ryan A Gallo; Wensi Tao; David Tse; Ravi Doddapaneni; Daniel Pelaez
Journal:  Pharmacol Res       Date:  2017-12-02       Impact factor: 7.658

3.  The TAg-RB murine retinoblastoma cell of origin has immunohistochemical features of differentiated Muller glia with progenitor properties.

Authors:  Sanja Pajovic; Timothy W Corson; Clarellen Spencer; Helen Dimaras; Marija Orlic-Milacic; Mellone N Marchong; Kwong-Him To; Brigitte Thériault; Mark Auspitz; Brenda L Gallie
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-29       Impact factor: 4.799

Review 4.  Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.

Authors:  Uma M Sachdeva; Joan M O'Brien
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

Review 5.  The genomic landscape of retinoblastoma: a review.

Authors:  Brigitte L Thériault; Helen Dimaras; Brenda L Gallie; Timothy W Corson
Journal:  Clin Exp Ophthalmol       Date:  2013-05-22       Impact factor: 4.207

6.  Inhibitor of apoptosis-stimulating protein of p53 (iASPP) is required for neuronal survival after axonal injury.

Authors:  Ariel M Wilson; Vince A Chiodo; Sanford L Boye; Nicholas C Brecha; William W Hauswirth; Adriana Di Polo
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

Review 7.  Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB.

Authors:  Jesús Hernández-Monge; Adriana Berenice Rousset-Roman; Ixaura Medina-Medina; Vanesa Olivares-Illana
Journal:  Genes Cancer       Date:  2016-09

8.  MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.

Authors:  D-L Qi; D Cobrinik
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

9.  Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development.

Authors:  Kwong-Him To; Sanja Pajovic; Brenda L Gallie; Brigitte L Thériault
Journal:  BMC Cancer       Date:  2012-02-15       Impact factor: 4.430

10.  Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma.

Authors:  Santiago Zugbi; Daiana Ganiewich; Arpita Bhattacharyya; Rosario Aschero; Daniela Ottaviani; Claudia Sampor; Eduardo G Cafferata; Marcela Mena; Mariana Sgroi; Ursula Winter; Gabriela Lamas; Mariona Suñol; Manuel Daroqui; Edgardo Baialardo; Beatriz Salas; Anirban Das; Adriana Fandiño; Jasmine H Francis; Fabiana Lubieniecki; Cinzia Lavarino; Ralph Garippa; Osvaldo L Podhajcer; David H Abramson; François Radvanyi; Guillermo Chantada; Andrea S Llera; Paula Schaiquevich
Journal:  Cancers (Basel)       Date:  2020-09-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.